QGEN

Qiagen NV

Add to Watchlist

Advanced Chart

48.040

-0.32(-0.662%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

48.140

Open

47.920

VWAP

48.00

Vol

1.29M

Mkt Cap

10.40B

Low

47.625

Amount

62.11M

EV/EBITDA(TTM)

15.64

Total Shares

221.85M

10.96B

EV/OCF(TTM)

P/S(TTM)

5.22

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

505.78M

+4.62%

0.570

+3.67%

539.30M

+3.47%

0.606

-0.62%

525.70M

+4.75%

0.586

+0.01%

Estimates Revision

The market is revising Downward the revenue expectations for Qiagen N.V. (QGEN) for FY2025, with the revenue forecasts being adjusted by -0.09% over the past three months. During the same period, the stock price has changed by 14.76%.

Revenue Estimates for FY2025

Revise Downward

-0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.15%

In Past 3 Month

Stock Price

Go Up

+14.76%

In Past 3 Month

14 Analyst Rating

5.14% Upside

Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 50.51 USD with a low forecast of 43.00 USD and a high forecast of 55.79 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

7 Hold

0 Sell

Moderate Buy

5.14% Upside

Current: 48.040

Low

43.00

Averages

50.51

High

55.79

5.14% Upside

Current: 48.040

Low

43.00

Averages

50.51

High

55.79

TD Cowen

Dan Brennan

Hold

maintain

$49 -> $52

2025-08-07

New

Reason

TD Cowen

Dan Brennan

Price Target

$49 -> $52

2025-08-07

New

maintain

Hold

Reason

TD Cowen analyst Dan Brennan raised the firm's price target on Qiagen to $52 from $49 and keeps a Hold rating on the shares. Following a modest beat and raise print, the conference call was largely "steady as she goes," with CEO/CFO discussing ongoing traction with the growth of their 5 Pillars enhanced via numerous R&D initiatives, navigating through tariff margin pressures, and a consistent capital allocation strategy, the firm notes.

Berenberg

Sam England

Buy

maintain

2025-07-24

Reason

Berenberg

Sam England

Price Target

2025-07-24

maintain

Buy

Reason

Berenberg analyst Sam England raised the firm's price target on Qiagen to EUR 50 from EUR 48 and keeps a Buy rating on the shares.

Morgan Stanley

Equal Weight

maintain

2025-06-30

Reason

Morgan Stanley

Price Target

2025-06-30

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Qiagen to EUR 43 from EUR 42 and keeps an Equal Weight rating on the shares.

BofA

Buy

maintain

$50 -> $53

2025-06-26

Reason

BofA

Price Target

$50 -> $53

2025-06-26

maintain

Buy

Reason

BofA raised the firm's price target on Qiagen to $53 from $50 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.

Barclays

Luke Sergott

Overweight

initiated

$55

2025-06-24

Reason

Barclays

Luke Sergott

Price Target

$55

2025-06-24

initiated

Overweight

Reason

Barclays analyst Luke Sergott initiated coverage of Qiagen with an Overweight rating and $55 price target. The firm says Qiagen screens positive among tools given its exposure to diagnostics and higher growth genomics markets on the life sciences side. In the current macro and policy-driven space, Barclays favors diagnostics given the minimal exposure to headwinds plaguing the overall industry including biotech funding and pharma tariffs. On genomics, volumes in the business continue to be supported by cutting-edge research and increasingly by clinical applications like liquid biopsy, the analyst tells investors in a research note.

Citi

Buy

maintain

$55

2025-05-22

Reason

Citi

Price Target

$55

2025-05-22

maintain

Buy

Reason

Citi kept a Buy rating on Qiagen with a $55 price target while adding an "upside 90-day short-term view" on the shares. Qiagen's "pillars of growth and strong" margin opportunity should provide a compelling backdrop for investors given the current state of the tools space, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Qiagen NV (QGEN.N) is 19.64, compared to its 5-year average forward P/E of 21.55. For a more detailed relative valuation and DCF analysis to assess Qiagen NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

21.55

Current PE

19.64

Overvalued PE

23.92

Undervalued PE

19.19

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

14.82

Current EV/EBITDA

13.58

Overvalued EV/EBITDA

16.29

Undervalued EV/EBITDA

13.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.16

Current PS

4.85

Overvalued PS

5.67

Undervalued PS

4.66